China Resources Pharmaceutical Group Ltd. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by HAN Yuewei, was filed 01 Apr 2020.
China Resources Pharmaceutical Group Ltd.: what insiders have been doing
Every trade that managers of China Resources Pharmaceutical Group Ltd. disclose to HKEX is tracked on this page. The company sits in the Health Care sector. China Resources Pharmaceutical Group Ltd. has had no insider filing for more than a year; the last one goes back to 3 September 2024.
Over the whole record (from 2020), the tally stands at 2 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Since the insiders bought
- +14.5%Entry HK$4.27 · Close at T+365 HK$4.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 300,000 sharesShareXHKGHKEX:DA20240903E00123
- 200,000 sharesShareXHKGHKEX:DA20220117E00089
- 200,000 shares@ HK$4.550566.3% of flowShareXHKGHKEX:DA20200401E00237Canonical exit: 30 Jun 2020 (T+90)
- 100,000 shares@ HK$4.664233.7% of flowShareXHKGHKEX:DA20200401E00100Canonical exit: 29 Jun 2020 (T+90)
4 of 4 declarations
About China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a Chinese company engaged in the distribution and manufacturing of pharmaceutical products. It primarily operates in the Hong Kong market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
